$Gyre Therapeutics (GYRE.US)$ I can't believe there are 11 units again 💧
Gratefully added again following yesterday 🐢...
I already have very little energy left 😥
I don't understand the meaning of inducing a drop at this timing 🤔
I can only hope that monkey smallpox will rampage in the country... If APDN can return to the acquisition cost, it will add up quite a bit for Jayko 😭
Gratefully added again following yesterday 🐢...
I already have very little energy left 😥
I don't understand the meaning of inducing a drop at this timing 🤔
I can only hope that monkey smallpox will rampage in the country... If APDN can return to the acquisition cost, it will add up quite a bit for Jayko 😭
Translated
3
3
$Applied DNA Sciences (APDN.US)$
The ultra-fine increase in the market responded to the continuing crisis assessment of the WHO emergency meeting...💧
If Emupo-kun starts rampaging at this timing in 🌾country, there's nothing to say...（−＿−；）
The ultra-fine increase in the market responded to the continuing crisis assessment of the WHO emergency meeting...💧
If Emupo-kun starts rampaging at this timing in 🌾country, there's nothing to say...（−＿−；）
Translated
3
$Applied DNA Sciences (APDN.US)$
On 11/22, there is news of a second WHO smallpox emergency meeting regarding the ongoing smallpox epidemic in Africa on 11/12, gold.
On 11/16, news of Trump appointing an anti-vaccine person as the head of the Insurance and Welfare Department.
And, at this timing, news of the first infection in the usa...
It feels like something unsettling is in the air 💧
I also had doubts about the fact that there were no reported infections in the USA until now, but it was during the election period...
Go for it APDN 🚀
On 11/22, there is news of a second WHO smallpox emergency meeting regarding the ongoing smallpox epidemic in Africa on 11/12, gold.
On 11/16, news of Trump appointing an anti-vaccine person as the head of the Insurance and Welfare Department.
And, at this timing, news of the first infection in the usa...
It feels like something unsettling is in the air 💧
I also had doubts about the fact that there were no reported infections in the USA until now, but it was during the election period...
Go for it APDN 🚀
Translated
7
2
On 11/22, there will be a second WHO emergency meeting on smallpox still raging in Africa, which will take place on November 12, gold news.
On 11/16, news of Trump appointing an anti-vaccine person as the head of the Insurance and Welfare Department.
And, at this time, news of the first infection in the USA...
I also feel like something is stirring up 💧
I also had doubts about the lack of infection reports in the USA until now, but it was during the election period...
Go for it APDN🚀
On 11/16, news of Trump appointing an anti-vaccine person as the head of the Insurance and Welfare Department.
And, at this time, news of the first infection in the USA...
I also feel like something is stirring up 💧
I also had doubts about the lack of infection reports in the USA until now, but it was during the election period...
Go for it APDN🚀
Translated
3
I'm eager for a rise, but I'm skeptical whether there will be a skyrocketing reaction tomorrow or later.
$Gyre Therapeutics (GYRE.US)$
In the content that the wise person asked GPT Sensei about,
Funding through a Mixed Shelf may also be utilized as a third-party allocation capital increase to partner companies.
As the Mixed Shelf enables flexible issuance of various types of securities, companies may consider implementing third-party allocation capital increases to partner companies as part of fundraising. Specifically, by allocating common stock or preferred stock from the pre-registered Mixed Shelf with the SEC to partner companies, it is possible to facilitate strategic partnerships, acquire funds tailored to specific business purposes.
By utilizing the registration framework of Mixed Shelf in this way, companies can dynamically choose their fundraising methods, making it a suitable approach for third-party capital increases for partnerships and strategic partnerships.
Expecting a rocket ride 🚀 with the use of third-party allocations with a major pharmaceutical company. m(__)m
In the content that the wise person asked GPT Sensei about,
Funding through a Mixed Shelf may also be utilized as a third-party allocation capital increase to partner companies.
As the Mixed Shelf enables flexible issuance of various types of securities, companies may consider implementing third-party allocation capital increases to partner companies as part of fundraising. Specifically, by allocating common stock or preferred stock from the pre-registered Mixed Shelf with the SEC to partner companies, it is possible to facilitate strategic partnerships, acquire funds tailored to specific business purposes.
By utilizing the registration framework of Mixed Shelf in this way, companies can dynamically choose their fundraising methods, making it a suitable approach for third-party capital increases for partnerships and strategic partnerships.
Expecting a rocket ride 🚀 with the use of third-party allocations with a major pharmaceutical company. m(__)m
Translated
8
2
$Gyre Therapeutics (GYRE.US)$
Do you mean bringing your own two-phase system?
Do you mean bringing your own two-phase system?
Translated
1
$Applied DNA Sciences (APDN.US)$
If Mr. Trump were to unexpectedly contract smallpox... Well, probably not, haha (just daydreaming).
If Mr. Trump were to unexpectedly contract smallpox... Well, probably not, haha (just daydreaming).
Translated
3
$Applied DNA Sciences (APDN.US)$
Infected with monkeypox without any travel history.
What happened... What happened.
Infected with monkeypox without any travel history.
What happened... What happened.
Translated
4
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)
待ち焦がれる男 OP kenau : I don't think hybrid new shares are a downside element. If it were just warrants, it would be diluted, but there is a high possibility that hybrid new shares will be exercised through partnerships or third-party allocation (such as major pharmaceutical companies).